433 related articles for article (PubMed ID: 20594801)
1. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
Fine PG; Messina J; Xie F; Rathmell J
J Pain Symptom Manage; 2010 Nov; 40(5):747-60. PubMed ID: 20594801
[TBL] [Abstract][Full Text] [Related]
2. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
Ashburn MA; Slevin KA; Messina J; Xie F
Anesth Analg; 2011 Mar; 112(3):693-702. PubMed ID: 21304148
[TBL] [Abstract][Full Text] [Related]
4. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients.
Nalamachu SR; Narayana A; Janka L
Curr Med Res Opin; 2011 Apr; 27(4):751-60. PubMed ID: 21288055
[TBL] [Abstract][Full Text] [Related]
5. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Weinstein SM; Messina J; Xie F
Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
[TBL] [Abstract][Full Text] [Related]
7. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Fine PG; Narayana A; Passik SD
Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
[TBL] [Abstract][Full Text] [Related]
8. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
Webster LR; Messina J; Xie F; Nalamachu S
J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
[TBL] [Abstract][Full Text] [Related]
9. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
Farrar JT; Messina J; Xie F; Portenoy RK
Pain Med; 2010 Sep; 11(9):1313-27. PubMed ID: 20807345
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
12. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
[TBL] [Abstract][Full Text] [Related]
14. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Nalamachu S; Hassman D; Wallace MS; Dumble S; Derrick R; Howell J
Curr Med Res Opin; 2011 Mar; 27(3):519-30. PubMed ID: 21208151
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
18. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
Taylor DR; Webster LR; Chun SY; Reinking J; Stegman M; Shoemaker S; Fortner B
Pain Med; 2007 Apr; 8(3):281-8. PubMed ID: 17371416
[TBL] [Abstract][Full Text] [Related]
19. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
Lecybyl R; Hanna M
Future Oncol; 2007 Aug; 3(4):375-9. PubMed ID: 17661711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
